zabalafin

Phase 2Small molecule

AAlphyn Biologics

zabalafin is one of 8 small molecule programs targeting Double-blind. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Double-BlindRecruiting

Double-BlindPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Double-Blind

#DrugCompanyPhaseTrials

Olumiant

Eli Lilly

Phase 3

1 2

Albenza

IImpax Laboratories, LLC

Phase 3

1 3

Everolimus and Lonafarnib

BBoston Children's Hospital

Phase 3

1 4

zabalafin

AAlphyn Biologics

Phase 2

1 5

Inosine Pranobex

NNewport Pharmaceuticals International

Preclinical

2 6

PORT-77

PPortal Therapeutics, Inc.

Phase 1

1 7

Western Therapy

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Preclinical

1 8

Interferon Alfa-N3

IInterferon Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Double-blind1 trial

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

Recruiting·AAlphyn Biologics·Phase 2·NCT06855745·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for zabalafin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zabalafin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zabalafin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alphyn Biologics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlphyn Biologics

zabalafin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Double-blind1 trial

References

Drug Info

Quick Facts

Related News